Loading
DP
Dicerna Pharmaceuticals Inc Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by FAMBROUGH DOUGLAS, was filed 10 Aug 2021.
Dicerna Pharmaceuticals Inc: what insiders have been doing
Dicerna Pharmaceuticals Inc is a Healthcare & Pharma company. Its directors and officers file their transactions with SEC (Form 4). No insider at Dicerna Pharmaceuticals Inc has published a filing in the past twelve months. The most recent one dates from 29 December 2021.
The full history, which starts in 2016, counts 9 purchases against 135 sales.
Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
336
Thresholds
n/a
Buy Volume
€2M
9 ops. · all time
Sell Volume
€195M
135 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2020FY ended December 2020 · cache
Income statement
RevenueUS$141.5M
Net income-US$97.1M-68.6% margin
Last declaration on 29 December 2021
Declarations336 total
3,080,237 shares@ US$38.2566.3% of flowCommon StockSEC:0000899243-21-050036:1
5,000 shares@ US$38.2538.1% of flowCommon StockSEC:0001399529-21-000202:1
18,100 shares@ US$38.2572.6% of flowCommon StockSEC:0001399529-21-000205:0
7,775 shares@ US$38.25100.0% of flowCommon StockSEC:0001399529-21-000203:0
3,333 shares@ US$38.25100.0% of flowCommon StockSEC:0001399529-21-000199:0
3,333 shares@ US$38.25100.0% of flowCommon StockSEC:0001399529-21-000204:0
16,157 shares@ US$38.25100.0% of flowCommon StockSEC:0001399529-21-000201:0
6,333 shares@ US$38.2577.9% of flowCommon StockSEC:0001399529-21-000202:0
5,032 shares@ US$38.25100.0% of flowCommon StockSEC:0001399529-21-000206:0
2,367 shares@ US$38.259.4% of flowCommon StockSEC:0001399529-21-000194:0
14,813 shares@ US$38.2562.1% of flowCommon StockSEC:0001399529-21-000196:0
231,431 shares@ US$38.2597.7% of flowCommon StockSEC:0001399529-21-000198:0
4,666 shares@ US$38.25100.0% of flowCommon StockSEC:0001399529-21-000195:0
3,333 shares@ US$38.25100.0% of flowCommon StockSEC:0001399529-21-000200:0
6,973 shares@ US$38.25100.0% of flowCommon StockSEC:0001399529-21-000193:0
3,333 shares@ US$38.25100.0% of flowCommon StockSEC:0000899243-21-050036:0
3,333 shares@ US$38.25100.0% of flowCommon StockSEC:0001399529-21-000197:0
1,675 shares@ US$38.050.6% of flowCommon StockSEC:0001399529-21-000173:1
5,348 shares@ US$38.051.5% of flowCommon StockSEC:0001399529-21-000174:1
602 shares@ US$38.055.9% of flowCommon StockSEC:0001399529-21-000178:1
1,675 shares@ US$38.050.9% of flowCommon StockSEC:0001399529-21-000175:1
752 shares@ US$38.0511.6% of flowCommon StockSEC:0001399529-21-000172:1
833 shares@ US$38.059.3% of flowCommon StockSEC:0001399529-21-000176:1
1,241 shares@ US$38.052.1% of flowCommon StockSEC:0001399529-21-000177:1
2,562 sharesCommon StockSEC:0001399529-21-000172:0
25 of 336 declarations
About Dicerna Pharmaceuticals Inc
Dicerna Pharmaceuticals Inc. (ticker: DRNA) was a U.S.-based biopharmaceutical company previously listed on the NASDAQ, in the United States, and known for its focus on RNA interference, or RNAi. Founded in 2006, Dicerna was headquartered in Lexington, Massachusetts, and built its corporate identity around a proprietary RNAi platform called GalXC, designed to silence disease-causing genes. The company’s business model was typical of a specialty biotech: heavy R&D spending, a platform-led pipeline, and a focus on high-unmet-need indications rather than large-scale commercial franchises. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1399529/000139952920000009/a2019_drnax10k.htm?utm_source=openai))
Strategically, Dicerna’s core competence was not broad commercial manufacturing or diversified product sales, but the development of subcutaneously delivered RNAi therapeutics with potentially infrequent dosing. That feature was a key part of its competitive positioning, because it suggested a more convenient treatment profile for chronic diseases than some existing options. Over time, the company expanded its technological narrative from its liver-focused GalXC programs into GalXC-Plus, a newer evolution intended to broaden the application of its RNAi science across additional therapeutic areas. Its pipeline and partner-facing programs included rare diseases and liver-related diseases such as primary hyperoxaluria, hepatitis B, alpha-1 antitrypsin deficiency, and other genetically defined conditions. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1399529/000139952921000042/drna-20201231.htm?utm_source=openai))
Read moreShow less
In competitive terms, Dicerna operated in a field dominated by better-capitalized RNAi leaders and large pharma partners. As a result, its value proposition was increasingly that of a technology platform and strategic asset rather than a standalone commercial growth story. That dynamic culminated in Novo Nordisk’s acquisition of Dicerna, completed in December 2021 for $38.25 per share in cash. After the transaction closed, Dicerna’s common stock was delisted from the NASDAQ Global Select Market, which is highly relevant for investors: DRNA is no longer an active listed equity today, even though it remains an important historical reference in the U.S. biotech space. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1399529/000119312521367447/d259099dex991.htm?utm_source=openai))
The most important recent corporate event, therefore, is the completed takeover by Novo Nordisk, which absorbed Dicerna’s RNAi technology into its broader rare disease and chronic disease strategy. Prior to that, Dicerna was a regular SEC filer, including Form 4 insider transaction disclosures, consistent with its status as a publicly traded U.S. issuer. For French-speaking investors, Dicerna is best understood as an innovation-driven biotechnology company founded in the United States, with a differentiated platform and a meaningful strategic exit rather than a continuing public-market equity story. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1259856/000139952921000174/0001399529-21-000174-index.htm?utm_source=openai))
